Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 14/20 | 0.55 |
| ▸ | TCF7L2 | Q9NQB0 | 14/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176645 | 0.91 | CTNNB1 (0.65) | CTNNB1TCF7L2 | |
| SCHEMBL4738857 | 0.90 | CTNNB1 (0.70) | CTNNB1TCF7L2 | |
| Hydrochloric Acid SCHEMBL4736410 | 0.89 | CTNNB1 (0.69) | CTNNB1TCF7L2 | |
| SCHEMBL4736957 | 0.87 | CTNNB1 (0.65) | CTNNB1TCF7L2 | |
| SCHEMBL4738362 | 0.82 | CTNNB1 (0.61) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| SCHEMBL4738259 | 0.82 | CTNNB1 (0.69) | CTNNB1TCF7L2RAB9ASMN1; SMN2 | |
| SCHEMBL4178332 | 0.81 | CTNNB1 (0.80) | CTNNB1TCF7L2 | |
| SCHEMBL4177266 | 0.81 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4177270 | 0.81 | CTNNB1 (0.81) | CTNNB1TCF7L2RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4735863 | 0.78 | CTNNB1 (0.67) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008086462-A2 | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS | WYETH (US) | 2008-07-17 | — | — | WO | disclosed |